Bringing a wealth of experience in early-stage investments, the fund manager has built a robust portfolio primarily in the biotechnology and healthcare sectors. Actively engaged in over 30 deals across North America and Europe, their strategic style emphasizes a data-driven approach, ensuring informed decision-making throughout the investment cycle. Noteworthy exits include successful IPOs and acquisitions, highlighting their proficiency in identifying high-potential opportunities. The manager's operator-first perspective fosters strong partnerships, enhancing value creation for portfolio companies.